MedTrace Logo

Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer

NCT01814449 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2013-03-20

No results posted yet for this study

Summary

The aim of our current study was to analyze whether 18F-labeled Fluoromisonidazole (1-(2-nitro-1-imidazolyl)- 2-hydroxy-3-fluoropropane \[18F-FMISO\]) PET/CT and expression of HIF-1-alpha could predict response of primary endocrine therapy in ER-positive breast cancer

Conditions

Interventions

OTHER

18FMISO PET/CT scan

The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.

DRUG

Letrozole

Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Guangyu Liu, M.D. · Cancer Hospital/Institute,Fudan University

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-02-28
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01814449 on ClinicalTrials.gov